Alere Inc. Release: Preliminary Results of Prospective Trial Suggest Warfarin May be a Safer Option for Patients than Alternative Therapies  
5/7/2012 9:42:02 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Today, at the 2012 Thrombosis and Hemostasis Summit of North America, Alere Inc. (NYSE: ALR) announced preliminary results from the largest study to date comparing warfarin (Coumadin®) and dabigatran (Pradaxa®) therapies administered in a real-world setting. The study was performed by Mark Wurster, MD, anticoagulation expert and Chief Medical Officer of Standing Stone, Inc., an Alere subsidiary. Findings reveal that complications necessitating therapy discontinuation occurred more frequently with dabigatran than with warfarin. Additionally, complications related to dabigatran appeared very early in treatment, with patients reporting issues, on average, after just less than four months of therapy.